OncoMatch/Clinical Trials/NCT07068607
Efficacy Comparison of Vonoprazan Combined With Different Antibiotics in Dual Therapy for Helicobacter Pylori Eradication: A Prospective, Randomized Controlled Clinical Trial
Is NCT07068607 recruiting? Yes, currently enrolling (Jun 2026). This Phase 4 trial studies multiple treatments for gastritis, indigestion, helicobacter pylori infection, gastric cancer, peptic ulcer.
Treatment: Vonoprazan · Tetracycline 500mg tid · Minocycline · Bismuth · Clarithromycin 500 mg · Amoxicillin — This study aims to evaluate the efficacy of vonoprazan combined with different antibiotics in dual therapy for Helicobacter pylori eradication treatment. Newly infected patients were randomly assigned to four groups: amoxicillin dual therapy, tetracycline dual therapy, minocycline dual therapy, and bismuth quadruple therapy. At the follow - up visit in the 6th week, urea breath test, rapid urease test, or Helicobacter pylori fecal antigen test will be conducted to confirm eradication.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Gastric Cancer
Demographics
Prior therapy
Cannot have received: Helicobacter pylori eradication treatment
Patients who have been definitely diagnosed with Hp infection and have received antibiotic eradication treatment
Cannot have received: anti-ulcer drugs (proton pump inhibitor)
Exception: PPI within 2 weeks before the Hp infection test
Patients who have been continuously using anti-ulcer drugs (including taking PPI within 2 weeks before the Hp infection test), antibiotics or bismuth complexes (more than 3 times a week within 1 month before screening)
Cannot have received: antibiotics
Exception: more than 3 times a week within 1 month before screening
Patients who have been continuously using anti-ulcer drugs (including taking PPI within 2 weeks before the Hp infection test), antibiotics or bismuth complexes (more than 3 times a week within 1 month before screening)
Cannot have received: bismuth complexes
Exception: more than 3 times a week within 1 month before screening
Patients who have been continuously using anti-ulcer drugs (including taking PPI within 2 weeks before the Hp infection test), antibiotics or bismuth complexes (more than 3 times a week within 1 month before screening)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07068607 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages